Literature DB >> 30441849

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.

Magdalena Koczkowska1, Natalia Krawczynska2,3, Maciej Stukan4, Alina Kuzniacka5,6, Izabela Brozek7, Marcin Sniadecki8, Jaroslaw Debniak9, Dariusz Wydra10, Wojciech Biernat11, Piotr Kozlowski12, Janusz Limon13, Bartosz Wasag14,15, Magdalena Ratajska16.   

Abstract

Constitutional loss-of-function pathogenic variants in the tumor suppressor genes BRCA1 and BRCA2 are widely associated with an elevated risk of ovarian cancer (OC). As only ~15% of OC individuals carry the BRCA1/2 pathogenic variants, the identification of other potential OC-susceptibility genes is of great clinical importance. Here, we established the prevalence and spectrum of the germline pathogenic variants in the BRCA1/2 and 23 other cancer-related genes in a large Polish population of 333 unselected OC cases. Approximately 21% of cases (71/333) carried the BRCA1/2 pathogenic or likely pathogenic variants, with c.5266dup (p.Gln1756Profs*74) and c.3700_3704del (p.Val1234Glnfs*8) being the most prevalent. Additionally, ~6% of women (20/333) were carriers of the pathogenic or likely pathogenic variants in other cancer-related genes, with NBN and CHEK2 reported as the most frequently mutated, accounting for 1.8% (6/333) and 1.2% (4/333) of cases, respectively. We also found ten pathogenic or likely pathogenic variants in other genes: 1/333 in APC, 1/333 in ATM, 2/333 in BLM, 1/333 in BRIP1, 1/333 in MRE11A, 2/333 in PALB2, 1/333 in RAD50, and 1/333 in RAD51C, accounting for 50% of all detected variants in moderate- and low-penetrant genes. Our findings confirmed the presence of the additional OC-associated genes in the Polish population that may improve the personalized risk assessment of these individuals.

Entities:  

Keywords:  BARD1; BRCA1/2; CHEK2; NBN; PARP1 inhibitor; low-penetrance gene; mismatch repair genes; next-generation sequencing; ovarian cancer

Year:  2018        PMID: 30441849      PMCID: PMC6266089          DOI: 10.3390/cancers10110442

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  43 in total

1.  Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.

Authors:  Maria D Iniesta; Michael A Gorin; Ling-Chen Chien; Samantha M Thomas; Kara J Milliron; Julie A Douglas; Sofia D Merajver
Journal:  Cancer Genet Cytogenet       Date:  2010-10-15

2.  The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.

Authors:  Michael Herman Chui; Paul Ryan; Jordan Radigan; Sarah E Ferguson; Aaron Pollett; Melyssa Aronson; Kara Semotiuk; Spring Holter; Keiyan Sy; Janice S Kwon; Anita Soma; Naveena Singh; Steven Gallinger; Patricia Shaw; Jocelyne Arseneau; William D Foulkes; C Blake Gilks; Blaise A Clarke
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

3.  The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia.

Authors:  Evgeny Imyanitov; Darya Prokofyeva; Natalia Bogdanova; Thilo Dörk
Journal:  Breast Cancer Res Treat       Date:  2014-12       Impact factor: 4.872

4.  The frequency of the BLM p.Q548X (c.1642C>T) mutation in breast cancer patients from Russia is no higher than in the general population.

Authors:  Maksim S Anisimenko; Anton E Kozyakov; Galina A Paul; Sergey P Kovalenko
Journal:  Breast Cancer Res Treat       Date:  2014-11-16       Impact factor: 4.872

5.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

6.  Exploring genomic alteration in pediatric cancer using ProteinPaint.

Authors:  Xin Zhou; Michael N Edmonson; Mark R Wilkinson; Aman Patel; Gang Wu; Yu Liu; Yongjin Li; Zhaojie Zhang; Michael C Rusch; Matthew Parker; Jared Becksfort; James R Downing; Jinghui Zhang
Journal:  Nat Genet       Date:  2016-01       Impact factor: 38.330

7.  High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

Authors:  Izabela Brozek; Karolina Ochman; Jarosław Debniak; Lucyna Morzuch; Magdalena Ratajska; Magdalena Stepnowska; Maciej Stukan; Janusz Emerich; Janusz Limon
Journal:  Gynecol Oncol       Date:  2007-11-07       Impact factor: 5.482

8.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.

Authors:  Izabela Brozek; Magdalena Ratajska; Magdalena Piatkowska; Anna Kluska; Aneta Balabas; Michalina Dabrowska; Dorota Nowakowska; Anna Niwinska; Jadwiga Rachtan; Jan Steffen; Janusz Limon
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

View more
  15 in total

1.  Clinical significance of RAD51C and its contribution to ovarian carcinogenesis.

Authors:  Xiao-Li Lu; Si-Sun Liu; Zhen-Fang Xiong; Fen Wang; Xia-Ying Li; Huan Deng
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

Review 2.  A Survey of Reported Disease-Related Mutations in the MRE11-RAD50-NBS1 Complex.

Authors:  Samiur Rahman; Marella D Canny; Tanner A Buschmann; Michael P Latham
Journal:  Cells       Date:  2020-07-13       Impact factor: 6.600

3.  BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.

Authors:  Malwina Suszynska; Magdalena Ratajska; Piotr Kozlowski
Journal:  J Ovarian Res       Date:  2020-05-02       Impact factor: 4.234

Review 4.  MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment.

Authors:  Lei Bian; Yiling Meng; Meichao Zhang; Dong Li
Journal:  Mol Cancer       Date:  2019-11-26       Impact factor: 27.401

Review 5.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

Review 6.  Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.

Authors:  Wejdan M Alenezi; Caitlin T Fierheller; Neil Recio; Patricia N Tonin
Journal:  Genes (Basel)       Date:  2020-07-27       Impact factor: 4.096

7.  A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review.

Authors:  P Loza; A Irmejs; Z Daneberga; E Miklasevics; E Berga-Svitina; S Subatniece; J Maksimenko; G Trofimovics; E Tauvena; S Ukleikins; J Gardovskis
Journal:  Hered Cancer Clin Pract       Date:  2021-01-19       Impact factor: 2.857

8.  Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations.

Authors:  Malwina Suszynska; Piotr Kozlowski
Journal:  Genes (Basel)       Date:  2020-07-15       Impact factor: 4.096

9.  Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer.

Authors:  Klara Lhotova; Lenka Stolarova; Petra Zemankova; Michal Vocka; Marketa Janatova; Marianna Borecka; Marta Cerna; Sandra Jelinkova; Jan Kral; Zuzana Volkova; Marketa Urbanova; Petra Kleiblova; Eva Machackova; Lenka Foretova; Jana Hazova; Petra Vasickova; Filip Lhota; Monika Koudova; Leona Cerna; Spiros Tavandzis; Jana Indrakova; Lucie Hruskova; Marcela Kosarova; Radek Vrtel; Viktor Stranecky; Stanislav Kmoch; Michal Zikan; Libor Macurek; Zdenek Kleibl; Jana Soukupova
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

10.  Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients.

Authors:  Dolores Gallardo-Rincón; Rosa María Álvarez-Gómez; Edgar Montes-Servín; Alfredo Toledo-Leyva; Elizabeth Montes-Servín; David Michel-Tello; Gabriela Alamilla-García; Antonio Bahena-González; Elizabeth Hernández-Nava; Veronica Fragoso-Ontiveros; Raquel Espinosa-Romero; Lucely Cetina-Pérez
Journal:  Transl Oncol       Date:  2019-12-20       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.